Dear Editor,

A recent report on a single center experience on "palliative low dose fortnightly methotrexate (MTX) in oral cancer" is very interesting. Chakraborty *et al*. reported "the fortnightly regimen of MTX was well-tolerated and showed a good clinical activity in this elderly cohort of patients with advanced oral cavity and oropharyngeal cancers."\[[@ref1]\] In fact, the effectiveness of palliative low dose fortnightly MTX has been mentioned in other cancers like prostate cancer.\[[@ref2]\] Nevertheless, the side effect of using MTX has to be mentioned and well-evaluated. Several possible side effects including to gastrointestinal and hematological side effects should be systematically evaluated. Sometimes, only the early signs impending pancytopenia in MTX toxicity could be observed.\[[@ref3]\] The good early sign is "cutaneous erosion," which is not mentioned in the report by Chakraborty *et al*.\[[@ref1]\] Finally, the use of additional supplementation to reduce the toxicity of metrotrexate like folic acid should be discussed.\[[@ref4]\]
